HURA (TuHURA) Forward P/E Multiple

Official company branding of TuHURA Biosciences (HURA)

TuHURA Biosciences, Inc. (HURA) is implementing AI-powered automated cell analysis systems to accelerate preclinical testing. Stock price fluctuations with the 0.00 metric reflect the specifics of a sector where demand for therapy remains stable, and security values depend on laboratory breakthroughs rather than macroeconomic trends. The business focuses on developing advanced oncology treatments and providing patient support.

tuhurabio.com - HURA Forward P/E Multiple (period 07/04/2022 - 11/17/2026)

Summary analytical data breakdowns for TuHURA Biosciences (HURA)

- current price and projected stock value:
Summary company analysis:TuHURA Biosciences Inc. HURA
Brand item of tuhurabio.com

Forward P/E assesses the current share price relative to projected earnings, accounting for the viability of the business model. This metric determines the extent of the premium paid for future income amid market volatility. For TuHURA Biosciences, Inc. (HURA), the forward P/E is critical, as the company consumes capital for clinical trials without generating operating revenue. This chart reveals a defensive discount amid rising liquidity shortage risks, which creates a high-risk investment profile.

Analysis of competing companies

Forward P/E Multiple ONC|HALO (Halozyme Inc.) - Future Price to Earnings Multiple|Forward P/E Multiple RVMD (revmed.com)|AAPG - Projected Price to Earnings|CGON: Projected Price to Earnings|URGN - Forward P/E Multiple|Bicara Bio (BCAX) - Future Price to Earnings|Personalis Corp - Future Price to Earnings Multiple|ERAS (Erasca Inc) - Forward P/E Multiple|Projected Price to Earnings Ratio Delcath Systems, Inc. DCTH|Projected Price to Earnings YMAB (Y-mAbs Corp)|Forward P/E Multiple Aura Bio (AURA)|Forward P/E Multiple CADL (Candel Therapeutics Inc.)|ARAY - Projected Price to Earnings|SLS - Future Price to Earnings|Actuate Therapeutics - Market Cap to Future Earnings Ratio|CTOR: Forward P/E Multiple|TARA: Market Cap to Future Earnings Ratio|Projected Price to Earnings FATE|WHWK: Future Price to Earnings Multiple|Projected Price to Earnings TCRX (TScan Therapeutics Inc)|Market Cap to Projected Earnings Champions Oncology Inc|Forward P/E Multiple XBIT (XBiotech Inc.)|Future Price to Earnings Multiple CVM|OS Therapies Inc. - Forward P/E Multiple|RADX - Forward P/E Multiple|ARTV: Forward P/E Multiple|ANL: Market Cap to Future Earnings Ratio|Projected Price to Earnings VERU|TPST: Future Price to Earnings Multiple|Future Price to Earnings xiliotx.com (XLO)|Renovaro - Price to Future Earnings Ratio|Future Price to Earnings Mural Oncology MURA|KAPA - Projected Price to Earnings|OKUR - Future Price to Earnings|GDTC - Forward P/E Multiple|Curis, Inc. (CRIS) - Future Price to Earnings|Projected Price to Earnings Apollomics, Inc.|Projected Price to Earnings THAR|Price to Future Earnings Ratio ADVB (Advanced Biomed)|Projected Price to Earnings GNPX (Genprex, Inc)|CLDI: Price to Expected Earnings Ratio|Future Price to Earnings sunshinebiopharma.com SBFM|XBIO - Projected Price to Earnings|SLRX: Projected Price to Earnings|Purple Biotech - Market Cap to Future Earnings Ratio|American Oncology Network (AONC) - Future Price to Earnings|Price to Future Earnings Ratio BGNE|Projected Price to Earnings CKPT|Future Price to Earnings ELEV|Forward P/E Multiple ICAD|Forward P/E Multiple Ikena Oncology Inc. (IKNA)|Forward P/E Multiple NTBL (Notable Labs Ltd)|Market Cap to Projected Earnings Viracta Therapeutics (VIRX)|MOR: Projected Price to Earnings|NAYA (NAYA Bio) - Price to Future Earnings Ratio|AAPGV: Forward P/E Multiple